These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17322491)

  • 1. Pegvisomant interference in GH assays results in underestimation of GH levels.
    Paisley AN; Hayden K; Ellis A; Anderson J; Wieringa G; Trainer PJ
    Eur J Endocrinol; 2007 Mar; 156(3):315-9. PubMed ID: 17322491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
    Manolopoulou J; Alami Y; Petersenn S; Schopohl J; Wu Z; Strasburger CJ; Bidlingmaier M
    Clin Chem; 2012 Oct; 58(10):1446-56. PubMed ID: 22908135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant, specific determination of growth hormone and pegvisomant in human serum.
    Ørskov H; Frystyk J; Nielsen C; Hansen AT; Weeke J; Jørgensen JO
    Growth Horm IGF Res; 2007 Oct; 17(5):431-4. PubMed ID: 17574889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting and solving the interference of pregnancy serum, in a GH immunometric assay.
    Dias ML; Vieira JG; Abucham J
    Growth Horm IGF Res; 2013; 23(1-2):13-8. PubMed ID: 23206731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
    Freda PU; Post KD; Powell JS; Wardlaw SL
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pegylated growth hormone receptor antagonist, pegvisomant, does not enter the brain in humans.
    Veldhuis JD; Bidlingmaier M; Bailey J; Erickson D; Sandroni P
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3844-7. PubMed ID: 20444908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy.
    Yin D; Vreeland F; Schaaf LJ; Millham R; Duncan BA; Sharma A
    Clin Cancer Res; 2007 Feb; 13(3):1000-9. PubMed ID: 17289896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
    Parkinson C; Burman P; Messig M; Trainer PJ
    J Clin Endocrinol Metab; 2007 Jan; 92(1):190-5. PubMed ID: 17077131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.
    McCutcheon IE; Flyvbjerg A; Hill H; Li J; Bennett WF; Scarlett JA; Friend KE
    J Neurosurg; 2001 Mar; 94(3):487-92. PubMed ID: 11235955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegvisomant-primed GH stimulation test.
    Radetti G; Wu Z; Elsedfy HH; El Kholy M; Bozzola M; Strasburger CJ
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):951-6. PubMed ID: 18031320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index.
    Arafat AM; Möhlig M; Weickert MO; Perschel FH; Purschwitz J; Spranger J; Strasburger CJ; Schöfl C; Pfeiffer AF
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1254-62. PubMed ID: 18171702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
    Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects.
    Brian SR; Bidlingmaier M; Wajnrajch MP; Weinzimer SA; Inzucchi SE
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3374-7. PubMed ID: 17595256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sex and assay method on serum concentrations of growth hormone in patients with acromegaly and in healthy controls.
    Markkanen H; Pekkarinen T; Välimäki MJ; Alfthan H; Kauppinen-Mäkelin R; Sane T; Stenman UH
    Clin Chem; 2006 Mar; 52(3):468-73. PubMed ID: 16439607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.